All Stories

  1. Share 35: A Liver in Time Saves Lives?
  2. Clinician assessments of health status predict mortality in patients with end-stage liver disease awaiting liver transplantation
  3. Posttransplant Metabolic Syndrome in the Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients (WISP-R) Pilot Trial
  4. Combined Effects of Recipient Age and Model for End-Stage Liver Disease Score on Liver Transplantation Outcomes
  5. Frailty Predicts Waitlist Mortality in Liver Transplant Candidates
  6. Expanded Criteria Donors
  7. Pediatric Liver Transplantation
  8. Clinical Allograft Rejection Syndromes in Liver Transplantation
  9. Research and Innovation in the Deceased Donor
  10. Sirolimus and mTOR Inhibitors in Liver Transplantation: The Wheel Has Come Full Circle
  11. Donor risk index for African American liver transplant recipients with hepatitis C virus
  12. Peri‐operative hyperglycemia is associated with delayed graft function in deceased donor renal transplantation
  13. Challenges to Research and Innovation to Optimize Deceased Donor Organ Quality and Quantity
  14. Offer patterns of nationally placed livers by donation service area
  15. Donor, Candidate, and Center Determinants of Death/Delisting vs. Transplantation and Post-Transplant Outcomes for MELD>30 Waitlist Candidates
  16. An Examination of Liver Offers to Candidates on the Liver Transplant Wait-List
  17. Can We Stop Waiting for Godot? Establishing Selection Criteria for Simultaneous Liver-Kidney Transplantation
  18. Biliary Leak With Tardus Parvus Arterial Waveform After Liver Transplantation
  19. Diabetes, Hypertension and Hyperlipidemia: Prevalence Over Time and Impact on Long-Term Survival After Liver Transplantation
  20. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma
  21. Patient, Center and Geographic Characteristics of Nationally Placed Livers
  22. Complete Immunosuppression Withdrawal and Subsequent Allograft Function Among Pediatric Recipients of Parental Living Donor Liver Transplants
  23. Transplantation of the Liver
  24. Center-Based Differences in Liver Quality: Why Do They Exist?
  25. Gender Differences in Liver Donor Quality Are Predictive of Graft Loss
  26. Kidney transplant performed after liver transplant: a single center experience
  27. The dilemma of high-risk deceased donor livers: Who should get them?
  28. Tolerance: Is It Achievable in Pediatric Solid Organ Transplantation?
  29. Management of the liver transplant patient
  30. Factors influencing liver transplant length of stay at two large-volume transplant centers
  31. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation
  32. Increased donor risk: Who should bear the burden?
  33. Long-term management of immunosuppression after pediatric liver transplantation: is minimization or withdrawal desirable or possible or both?
  34. Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection
  35. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: An intention-to-treat analysis
  36. Are we splitting hairs over split livers?
  37. Steatotic livers for liver transplantation—life-saving but at a cost
  38. Allocation policy for hepatocellular carcinoma in the MELD era: Room for improvement?
  39. Liver-specific loss of β-catenin results in delayed hepatocyte proliferation after partial hepatectomy
  40. Living Donor Kidney Transplant Recipients and Clinical Trials: Participation Profiles and Impact on Post-Transplant Care
  41. How can we define expanded criteria for liver donors?
  42. Striving for Perfection: Evaluation of the Right Lobe Live Liver Donor
  43. Characteristics Associated with Liver Graft Failure: The Concept of a Donor Risk Index
  44. In a MELD-based economy, how can we fight off inflation?
  45. Trends over a decade of pediatric liver transplantation in the United States
  46. Liver-specific loss of β-catenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice
  47. PELD: Working Well, But Only Half of the Time?
  48. Impact of Sirolimus on Early Graft Function after Deceased-Donor Kidney Transplantation
  49. An Older Liver in the Hand, or a (Possibly) Younger Liver in the Bush?
  50. BKV in Simultaneous Pancreas-Kidney Transplant Recipients: A Leading Cause of Renal Graft Loss in First 2 Years Post-Transplant
  51. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation
  52. Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation
  53. Comparison of Outcomes after Delayed Graft Function: Sirolimus-Based Versus Other Calcineurin-Inhibitor Sparing Induction Immunosuppression Regimens
  54. Polyomavirus-Associated nephropathy in simultaneous Kidney-Pancreas transplant recipients: a Single-Center experience
  55. Organ Donors with Malignant Gliomas: An Update
  56. Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury
  57. Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation
  58. 429 HCV etiology of liver disease is strongly associated with early acute rejection following liver transplantation
  59. Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantation
  60. Approach to the Management of Allograft Recipients Following the Detection of Hepatitis B Virus in the Prospective Organ Donor
  61. POST-TRANSPLANT DIABETES MELLITUS AND RECURRENT GRAFT HEPATITIS IN HEPATITIS C (+) LIVER TRANSPLANT RECIPIENTS.
  62. Liver Transplantation